ProfileGDS5678 / 1430741_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.249359
GSM967853U87-EV human glioblastoma xenograft - Control 22.223529
GSM967854U87-EV human glioblastoma xenograft - Control 32.225839
GSM967855U87-EV human glioblastoma xenograft - Control 42.178829
GSM967856U87-EV human glioblastoma xenograft - Control 52.170439
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.277849
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.239099
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.200659
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.188369
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.210799
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.2089
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.19519
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.214269
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.214079